Effective immediately, Karen B. DeSalvo, MD, MPH, will be stepping down as national coordinator for health information technology to assist HHS in the fight against Ebola.
Effective immediately, Karen B. DeSalvo, MD, MPH, will be stepping down as national coordinator for health information technology (IT) to assist HHS in the fight against Ebola.
Dr DeSalvo will become the acting assistant secretary for health, overseeing 12 core public health offices, including the surgeon general’s office, and the US Public Health Service Commissioned Corps, according to HHS. The Office of the Assistant Secretary for Health also oversees 10 regional health offices and 10 Presidential and Secretaarial advisory committees. Her office leads policy recommendation development for public health issues. In her farewell email to staff at the Office of the National Coordinator (ONC), she wrote that her new job will allow her to be part of the team responding to Ebola.
As part of her new role, Dr DeSalvo will work directly with HHS Secretary Sylvia Mathews Burwell on pressing public health issues, something she is not unfamiliar with. In the aftermath of Hurricane Katrina, Dr DeSalvo was credited with leading efforts to rebuild the public health infrastructure in New Orleans in the aftermath of the disaster. She worked to set up mobile clinics so she and other physicians could care for patients.
She wrote about her experience and the “logistic nightmare” presented with limited telephone and Internet access in her “Letter from New Orleans” in the Annals of Internal Medicine. Dr DeSalvo wrote that she dreamt of transforming the post-hurricane healthcare system to be proactive and able to “identify at-risk patients before their conditions deteriorate.”
As Dr DeSalvo steps down from her position with ONC, Lisa Lewis, ONC’s chief operating officer will serve as acting national coordinator, according to ONC.
Dr DeSalvo was the fifth national coordinator in the history of ONC, replacing Farzad Mostashari, MD, just 10 months ago.
Around the Web
HHS Reshuffles Amid Ebola Crisis
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More